Clinical Trial Detail

NCT ID NCT03829319
Title Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Merck Sharp & Dohme Corp.
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Lenvatinib + Pembrolizumab + Pemetrexed Disodium

Carboplatin + Pembrolizumab + Pemetrexed Disodium

Cisplatin + Lenvatinib + Pembrolizumab + Pemetrexed Disodium

Cisplatin + Pembrolizumab + Pemetrexed Disodium

Age Groups: senior adult

Additional content available in CKB BOOST